Jeff Aronin

Jeff Aronin
Born December 8, 1967
Education BA (Marketing) 1989[1]
Alma mater Northern Illinois University[1]
Occupation CEO and founder of Marathon Pharmaceuticals LLC


Jeff Aronin (born December 8, 1967) is a biopharmaceutical executive. He is chairman, CEO, and founder of Marathon Pharmaceuticals LLC, a privately owned company headquartered in Northbrook, Illinois.[2] He is also chairman, CEO and founder of Paragon Pharmaceutical Capital, LLC, an investment firm that backs healthcare companies.[3]

Career

Prior to operating Marathon and Paragon, Aronin founded Ovation Pharmaceuticals LLC in 2000 and served as its chairman and CEO for nine years. On February 9, 2009, it was announced that H. Lundbeck A/S, a Danish pharmaceutical company, had purchased Ovation for $900 million.[4] Chicago Mayor Rahm Emanuel appointed Aronin to the board of directors of World Business Chicago[5] and co-chair of ChicagoNEXT.[6] Aronin is also co-chair[7] MATTER, a start-up center in Chicago for next-generation healthcare technology companies that opened in February 2015.[8] He also serves on the board of trustees of Discover Financial Services[9] and on the board of trustees of the Museum of Science and Industry.[10]

Deflazacort

On February 13, 2017, Aronin announced that Marathon would delay the launch of deflazacort (Emflaza) an "old drug"[11] which is used to treat Duchenne muscular dystrophy, a rare disease that affects boys, amid controversy over the steep price Marathon was asking for the drug - $89,000-a-year. In Canada, the same drug could be purchased for around $1 per tablet.[12] According to The Wall Street Journal, the price Marathon was proposing was "roughly 70 times" more than it would cost overseas.[13] In a 2015 Chicago Tribune article, parents had expressed concerns that if deflazacort were approved in the United States, FDA guidelines seemed to suggest that parents would not "be able to order it from another country." They feared a "U.S. drug could be vastly more expensive than current international rates, leaving a question about insurance coverage."[14] Senator Bernie Sanders and Rep. Elijah Cummings are investigating the price of the drug as part of a larger investigation about the cost of pharmaceuticals.[11]

References

  1. 1 2 Colleen Leonard, The Man Behind Global Pharmas
  2. ↑ "How Paragon’s Jeffrey Aronin built two companies out of niche drugs". Voices. Sun-Times Media, LLC. Retrieved 14 July 2014.
  3. ↑ Kapos, Shia (9 March 2010). "Jeff Aronin back in business with new pharma company". Crain's Chicago Business. Retrieved 14 July 2014.
  4. ↑ Graham, Meg. "Jeff Aronin of Marathon Pharmaceuticals on life after a $900M exit". Chicagotribune.com. The Chicago Tribune. Retrieved 3 December 2015.
  5. ↑ "Board of Directors". World Business Chicago. Retrieved 14 July 2014.
  6. ↑ "Leadership". World Business Chicago. Retrieved 14 July 2014.
  7. ↑ Pletz, John (11 February 2014). "The formation of Matter, Chicago's new health-tech incubator". Crain's Chicago Business. Retrieved 14 July 2014.
  8. ↑ "Governor Quinn Announces MATTER, a New Healthcare Technology Startup Hub". MATTER. Retrieved 14 July 2014.
  9. ↑ "Board of Directors". Discover. Retrieved 14 July 2014.
  10. ↑ "Museum of Science and Industry Leadership". Museum of Science and Industry. Retrieved 14 July 2014.
  11. 1 2 Joseph Walker and Susan Pulliam (February 13, 2017), Firm Delays Muscular Dystrophy Drug U.S. Launch Amid Criticism of $89,000 Price: Sanders, Cummings investigating how Marathon Pharmaceuticals set hefty price tag for an old drug, The Wall Street Journal, retrieved February 13, 2017, Marathon Pharmaceuticals LLC CEO Jeffrey Aronin said it would delay the U.S. launch of its expensive muscular dystrophy drug amid mounting criticism of its $89,000-a-year price
  12. ↑ Clifton Sy Mukherjee (February 10, 2017). "Brainstorm Health Daily". Retrieved February 13, 2017.
  13. ↑ Joseph Walker and Susan Pulliam (February 13, 2017), Marathon Pharmaceuticals to Charge $89,000 for Muscular Dystrophy Drug After 70-Fold Increase, The Wall Street Journal, retrieved February 13, 2017, FDA-approved deflazacort treats rare type of disease affecting boys
  14. ↑ Ellen Jean Hirst (January 19, 2015), Duchenne muscular dystrophy drug could get OK for U.S. sales in 2016, The Chicago Tribune, retrieved February 13, 2017, has been shown to prolong lives ... a progressive and fatal disease that has no drug treatment available in the US



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.